These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 35800740)
1. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses. Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740 [TBL] [Abstract][Full Text] [Related]
2. The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. Shang M; Chi Y; Zhang J; Chang J; Yang H; Yin S; Tan Q; Man X; Li H Front Oncol; 2021; 11():706606. PubMed ID: 35070953 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167 [TBL] [Abstract][Full Text] [Related]
4. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates. Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298 [TBL] [Abstract][Full Text] [Related]
5. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
6. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062 [TBL] [Abstract][Full Text] [Related]
7. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727 [TBL] [Abstract][Full Text] [Related]
8. [Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers]. Yang YL; Song YM; Xue HQ; Sun H; Li YQ; Qian XL; Jiao J; Li KP; Zhang H; Guo XJ Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):165-169. PubMed ID: 36781238 [No Abstract] [Full Text] [Related]
9. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status. Attia S; Abd El Hafez A; Abdel-Aziz A; Elmetwaly S; Mokhtar N Asian Pac J Cancer Prev; 2022 Apr; 23(4):1433-1444. PubMed ID: 35485706 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit. Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446 [TBL] [Abstract][Full Text] [Related]
11. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC). Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710 [TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815 [TBL] [Abstract][Full Text] [Related]
14. Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance. Mondal SK; Bhattacharya S; Sarkar AP; Saha R J Cancer Res Ther; 2023 Apr; 19(Supplement):S81-S86. PubMed ID: 37147987 [TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Wang X; Liu Y Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408 [TBL] [Abstract][Full Text] [Related]
16. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809 [TBL] [Abstract][Full Text] [Related]
17. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109 [TBL] [Abstract][Full Text] [Related]
19. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M Cancer Manag Res; 2017; 9():741-750. PubMed ID: 29238224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]